Syrna Therapeutics
Del Mar, US · Founded 2020 · Delaware corporation · 2 known investors
Syrna Therapeutics is a biotech company developing small-molecule covalent translation inhibitors that bind and modify structured domains in the mRNA of disease-causing proteins to block their expression. It uses a 3D structure-guided drug discovery platform, with lead programs in immunology and neurodegeneration and a broader pipeline spanning metabolic disease and oncology.
Also known as Syrna · Syrna Therapeutics, Inc.
Founders & leadership
Board
Investors · 2
Reported raises · per SEC filings
Form D private placements$10.9M disclosed across 1 round · 2023
▶$10.9MraisedAug 2023 · 3 investors · BiotechnologyRule 506(b)
- Thomas HermannDirector
- Aiden AcevesDirector
- Joel DudleyDirector
- David WeitzExecutive Officer, Director
- Offering amount
- $10.9M
- Amount sold
- $10.9M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Syrna Therapeutics, Inc. is a biotechnology company working on small-molecule drugs that silence disease-causing proteins by covalently modifying their messenger RNA. Its inhibitors bind unique sites within structured domains of a target mRNA and chemically modify them, obstructing the ribosome and preventing translation of the encoded protein. The company states that this mechanism is independent of the underlying biology of the site being modified, so it can in principle be applied to any mRNA containing a druggable structured domain.
The company's discovery engine is a 3D structure-informed platform that identifies structured domains in the mRNA of disease-causing proteins and validates them as small-molecule target sites. Syrna characterizes these domains as large, stable, persistent and complex, with sequence and structural features that support selective, high-affinity binding. It reports routinely identifying druggable structured domains in human mRNA and having found such domains in the mRNA of more than 25 disease-causing proteins spanning diverse protein classes.
Syrna's disclosed portfolio comprises programs in early lead optimization against immunology and neurodegeneration targets, supported by a broader asset base of druggable structured mRNA domains in immunology, neurodegeneration, metabolic disease and oncology, several of which are accompanied by chemistry assets.
Founding story
Syrna was founded on the premise that halting production of disease-causing proteins by interfering with cellular translation requires a fundamentally new approach, pairing 3D structure-guided discovery for mRNA with a universal translation-inhibition mechanism. Co-founders include David Weitz, President and CEO, and Thomas Hermann, acting CTO.
Business model
Syrna is a therapeutics developer advancing an internal pipeline of small-molecule mRNA-targeting programs and states that it welcomes partnering opportunities to accelerate its portfolio.
Traction
Programs targeting immunology and neurodegeneration mRNAs are in early lead optimization, and the company reports identifying druggable structured domains in the mRNA of more than 25 disease-causing proteins, with chemistry assets attached to many of the broader portfolio targets.
Latest developments
The company emerged from stealth with its covalent translation inhibitor platform, and on January 7, 2026 was featured on the Innovating Tomorrow's Medicine interview series, where CEO David Weitz discussed targeting mRNA with small molecules.
▸Full profile — market position, technology, go-to-market, geography
Market position
Syrna describes itself as the first mRNA-focused structure-guided drug discovery company, noting that structure-guided methods, while established for protein targets, have been absent from small-molecule programs aimed at mRNA.
Technology
Syrna applies structure-guided drug discovery — an approach historically used for protein targets — to mRNA, making 3D structures of mRNA accessible for both target identification and medicinal chemistry. Resolving the three-dimensional structure of drug-binding sites in mRNA informs where and how small molecules bind, which the company uses to design covalent inhibitors that modify the RNA and block ribosomal translation of the target transcript.
Go-to-market
The company advances proprietary programs from target identification through lead optimization and seeks partnerships to accelerate portfolio development.
Prospective partners and licensees in the pharmaceutical industry, with therapeutic programs directed at immunology, neurodegeneration, metabolic disease and oncology indications.
Geography
Syrna Therapeutics is headquartered at 10835 Road to the Cure, Suite 150, San Diego, California 92121.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
2 people who came through Syrna Therapeutics went on to found or lead other companies.
Competitors · 7
by search overlap
Companies competing with Syrna Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 2
launches, deals, and filingsCEO David Weitz appeared in a video interview, 'Targeting mRNA with Small Molecules,' on the Innovating Tomorrow's Medicine series covering healthcare, biotechnology and life sciences.
The company announced it was coming out of stealth with a covalent translation inhibitor approach targeting mRNA, built on 3D structure-guided drug discovery.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- Syrna Therapeuticssyrnatx.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Syrna Therapeutics do?
- Syrna Therapeutics develops small-molecule covalent translation inhibitors that block protein expression by modifying mRNA.
- Who are Syrna Therapeutics's investors?
- Syrna Therapeutics's investors include Innovation Endeavors, Insight Partners.
- How much funding has Syrna Therapeutics raised?
- Syrna Therapeutics has disclosed $10.9M raised across 1 round.
- Where is Syrna Therapeutics headquartered?
- Syrna Therapeutics is headquartered in Del Mar, US.